Actively Recruiting
Tumor-Targeted-NIR-II Fluorescent Molecular Probes for the Identification of Breast Cancer Tissue and SLN Metastatic Status
Led by Yunnan Cancer Hospital · Updated on 2024-12-03
40
Participants Needed
1
Research Sites
68 weeks
Total Duration
On this page
Sponsors
Y
Yunnan Cancer Hospital
Lead Sponsor
X
Xiang'an Hospital of Xiamen University
Collaborating Sponsor
AI-Summary
What this Trial Is About
Accurate evaluation of tumor boundaries in breast-conserving surgery is closely associated with reducing the second operation of patients. Meanwhile, accurately assessing sentinel lymph node (SLN) metastasis is crucial for determining the extent of axillary lymph node dissection (ALND) and minimizing complications. Near-infrared-II (NIR-II) fluorescence imaging using molecular agents has shown promise for in situ imaging during resection. However, very effective probes can be applied to clinical trials up to now, which limits the clinical application of fluorescence imaging. Here we developed a new technology that can quickly differentiation between cancer and para-cancer tissue as well as metastatic and normal sentinel lymph nodes(SLN). In brief, the fresh tissues were incubated with the probe immediately after intraoperative resection and imaged to identify the tumor area and distinguish the metastatic status of SLN. The accuracy of fluorescence imaging was confirmed by pathological diagnosis.
CONDITIONS
Official Title
Tumor-Targeted-NIR-II Fluorescent Molecular Probes for the Identification of Breast Cancer Tissue and SLN Metastatic Status
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult patients between 18-75 years of age
- Female
- Patients presenting with a breast nodule or mass presumed to be resectable on pre-operative assessment
- Good operative candidate
- Subject capable of giving informed consent and participating in the process of consent
You will not qualify if you...
- Patients unable to participate in the consent process
- Patients with contraindications to surgery, such as serious cardiopulmonary disease or coagulation dysfunction
- Other conditions that the researcher considers inappropriate to participate in the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Yunnan Cancer Hospital
Kunming, Yunnan, China, 650118
Actively Recruiting
Research Team
Y
Yuanyuan Zhu,Doctor
CONTACT
W
Weiling Chen, Doctor
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here